Association of Medicaid Expansion with Diagnosis and Management of Colon Cancer

Value of enhanced CT machine learning models combined with clinicoradiological characteristics in predicting lymphatic tissue metastasis in colon cancer

This study aimed to assess the effectiveness of various machine learning models in identifying lymph node metastasis in colon cancer patients and to explore the potential benefits of combining clinicoradiological and radiomics features for improved diagnosis. A total of 260 patients with pathologically confirmed colon cancer were retrospectively included in study center 1 and study center 2 from January 2015 to August 2024. A total of 198 patients with colon cancer in center 1 were randomly divided into a training set (n = 138) and an internal testing set (n = 60) at a ratio of 7:3. Patients in center 2 were included in the external testing set (n = 62). Five clinical radiological features were used to establish a clinical model. Radiomics features were extracted from the computed tomography venous phase images, and four classifiers, including logistic regression, support vector machine, decision tree, and k‑nearest neighbor, were used to build machine learning models. In addition, a combined model was constructed by joining clinical, radiological, and radiogenomic features. The performance of these models was evaluated in terms of accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating curve (ROC) and calibration curves in the training set, internal testing set, and external testing set to determine the diagnostic model with the highest predictive efficiency and to evaluate the stability of the model. Among the four machine learning models, the SVM model had the best predictive performance, with an area under the ROC (AUC) of 0.813, 0.724, and 0.721 for the training set, internal testing set, and external testing set, respectively. The clinical model, radiomics model, and combined model had an AUC of 0.823, 0.813, 0.817, 0.508, 0.724, 0.751, 0.582, 0.721, and 0.744 in the training set, internal testing set, and external testing set, respectively. In conclusion, the combined model performed significantly better than the clinical model (p = 0.017, 0.038), but there was no significant difference between the radiomics model and the combined model (p = 0.556, 0.614).

Impact of Medicaid Expansion on Incidence and Mortality from Gastric and Esophageal Cancer

BACKGROUND AND AIMS

Individuals in Medicaid expanded states have increased access to treatment for medical conditions and other health care resources. Esophageal and gastric cancer are associated with several modifiable risk factors (e.g. smoking, drinking, Helicobacter pylori infection). The impact of Medicaid expansion on these cancers incidence and mortality remains uninvestigated.

METHODS

We evaluated the association between Medicaid expansion and gastric and esophageal cancer incidence and mortality in adults aged 25-64. We employed an observational design using a difference-in-differences method with state level data, from 2010 to 2017. Annual, age-adjusted gastric and esophageal cancer incidence and mortality rates, from the CDC Wonder Database, were analyzed. Rates were adjusted for by several socio-demographic factors.

RESULTS

Expansion and non-expansion states were similar in percent Hispanic ethnicity and female gender. The non-expansion states had significantly higher proportion of Black race, diabetics, obese persons, smokers, and those living below the federal poverty line. Adjusted analyses demonstrate that expansion states had significantly fewer new cases of gastric cancer: - 1.6 (95% CI 0.2-3.5; P = 0.08) per 1,000,000 persons per year. No significant association was seen between Medicaid expansion and gastric cancer mortality (0.46 [95% CI - 0.08 to 0.17; P = 0.46]) and esophageal cancer incidence (0.8 [95% CI - 0.08 to 0.24; P = 0.33]) and mortality (1.0 [95% CI - 0.06 to 0.26; P = 0.21]) in multivariable analyses.

CONCLUSION

States that adopted Medicaid expansion saw a decrease in gastric cancer incidence when compared to states that did not expand Medicaid. Though several factors may influence gastric cancer incidence, this association is important to consider during health policy negotiations.